What's New in the Treatment Development Pipeline for Patients with Diabetes?

In this clip, Jennifer Goldman, PharmD, CDE, BC-ADM FCCP, who is a professor of pharmacy practice at Massachusetts College of Pharmacy and Health Sciences School of Pharmacy, discusses with Pharmacy Times the treatment pipeline and what's next for treating patients with diabetes.

Dr. Goldman discussed managing diabetes with insulin/GLP-1 receptor agonist combinations during a special session held in conjunction with APhA2017.

Transcript

"We’re going to have a lot more options for helping our patients. If we think back to 20 years ago, when we had NPH insulin, regular insulin, sulfonylureas, and we didn’t gain a lot of new medications early on so we had metformin 1995 and the glitazones. It really wasn’t until the last decade that we had this uptick of so many different classes of drugs. So now we’ll have more options. We talked earlier about 1 in 3 by 2050 having diabetes, now we have more options with more different mechanisms for patients so we can achieve better glycemic control and have better outcomes for them."